Do Hedge Funds Love Acorda Therapeutics Inc (ACOR)?
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However...
Posts Tagged ‘NASDAQ:ACOR’
Hedge Fund and Insider Trading News: Bill Ackman, Marshall Wace, Greenlight Capital, Becton Dickinson and Co (BDX), On Track Innovations Ltd (OTIVF), and More
Hedge Fund Marshall Wace Takes Short Position in Danske Bank (Reuters) COPENHAGEN (Reuters) – Hedge fund Marshall Wace is betting on Danske Bank...
Hedge Funds Are Getting Burned By Acorda Therapeutics Inc (ACOR)
After several tireless days we have finished crunching the numbers from nearly 750 13F filings issued by the elite hedge funds and other investment firms...
Were Hedge Funds Right About Dumping Acorda Therapeutics Inc (ACOR)?
We are still in an overall bull market and many stocks that smart money investors were piling into surged through October 17th. Among them, Facebook and...
Here’s What Hedge Funds Think About Acorda Therapeutics Inc (ACOR)
“The global economic environment is very favorable for investors. Economies are generally strong, but not too strong. Employment levels are among...
Is Acorda Therapeutics Inc (ACOR) A Good Stock To Buy?
Concerns over rising interest rates and expected further rate increases have hit several stocks hard during the fourth quarter. NASDAQ and Russell 2000...
Hedge Fund and Insider Trading News: Israel Englander, Omega Advisors, Jabre Capital, Red Lion Hotels Co. (RLH), Amkor Technology, Inc. (AMKR), and More
Omega, Jabre Capital Among Hedge Fund Casualties in Dismal 2018 (Bloomberg) (Bloomberg) — It has been yet another year to forget in the world of...
Hedge Fund and Insider Trading News: David Tepper, Soros Fund Management, Lixte Biotechnology Holdings Inc (LIXT), Acorda Therapeutics Inc (ACOR), Achaogen Inc (AKAO), and More
David Tepper: Fed Is Done Supporting Stock Prices, So Cash Is ‘Not So Bad’ As An Investment Now (CNBC) Hedge fund titan David Tepper said Thursday...
Is Acorda Therapeutics Inc (ACOR) A Good Stock To Buy?
The fourth quarter was a rough one for most investors, as fears of a rising interest rate environment in the U.S, a trade war with China, and a more or...
Hedge Fund and Insider Trading News: John Paulson, Ray Dalio, International Flavors & Fragrances Inc (IFF), KAR Auction Services Inc (KAR), Second Sight Medical Products Inc (EYES), and More
Paulson & Co to Ask Detour Gold for Special Meeting for Board Overhaul (Reuters) (Reuters) – Activist investor John Paulson’s hedge fund on...
13D Filing: Scopia Capital and Acorda Therapeutics Inc (ACOR)
Acorda Therapeutics Inc (NASDAQ:ACOR): Matt Sirovich And Jeremy Mindich’s Scopia Capital filed an amended 13D. You can check out Scopia Capital&#...
Hedge Fund and Insider Trading News: Och-Ziff Capital Management, Jana Partners, Intrexon Corp (XON), Legacy Reserves LP (LGCY), and More
Och-Ziff Capital Names Robert Shafir as CEO (Reuters) (Reuters) – Och-Ziff Capital Management on Tuesday named Robert Shafir as its new chief executive...
Hedge Fund and Insider Trading News: Elliot Management, Brevan Howard, Acorda Therapeutics Inc (ACOR), Cognizant Technology Solutions Corp (CTSH), and More
Singer’s Elliott Management Buys Sky Stake Ahead of Vote (Bloomberg) Elliott Management Corp., the hedge fund founded by billionaire Paul Singer...
Market Movers Today: Nike Inc (NKE), Forward Industries, Inc. (FORD), International Business Machines Corp (IBM), and More
Nike Inc (NYSE:NKE) (TheStreet) Shares of Nike (NYSE:NKE) rose over 3% Friday morning following an upgrade by Wedbush to Outperform (from Neutral) with...
13D Filing: Scopia Capital and Acorda Therapeutics Inc (ACOR)
Acorda Therapeutics Inc (NASDAQ:ACOR): Matt Sirovich and Jeremy Mindich’s Scopia Capital filed an amended 13D. You can check out Scopia Capital&#...
13D Filing: Scopia Capital and Acorda Therapeutics Inc (ACOR)
You can access the original SEC filing by clicking here. Ownership Summary Table Page 1 of 10 – SEC Filing UNITED STATES SECURITIES AND EXCHANGE...
13G Filing: Partner Fund Management and Acorda Therapeutics Inc (ACOR)
You can access the original SEC filing by clicking here. Ownership Summary Table Page 1 of 13 – SEC Filing UNITED STATES SECURITIES AND EXCHANGE...
Here’s What Is Happening In Financial Markets Today?
1. US Stock Market: “Wall Street stocks on Monday were aiming to start the second quarter with tepid gains. Investors were set to take cues from a handful...
What Is Going On In The Financial Markets Today?
1. US Stock Market: “U.S. stocks were slightly lower on Friday, dragged down by technology stocks as investors locked in gains of what is likely to...
Generic Competitors A Looming Threat For Acorda Therapeutics Inc (ACOR)
In order to ensure an extension of Ampyra’s protection to 2026, Acorda Therapeutics Inc (NASDAQ:ACOR) must fight off competition from competitors such...
Can Acorda Therapeutics Inc (ACOR) Give Eli Lilly And Co (LLY) A Run For Its Money In Migraine Drug Market?
Acorda Therapeutics Inc (NASDAQ:ACOR) inhaled migraine candidate CVT-427 is seen by Janney analyst Ken Trbovich as likely to give Eli Lilly and Co (NYSE...
Acorda Therapeutics Inc (ACOR) Continues To Fall From Favor With Top Investors
Hedge funds run by legendary names like Nelson Peltz and David Tepper make billions of dollars a year for themselves and their super-rich accredited investors...
Biotech Movers And Shakers: Mast Therapeutics, Inc. (MSTX) And Acorda Therapeutics Inc (ACOR)
To find a winner in the biotech space this week, all you’d need to do is throw a dart at a basket of micro-caps. Sub $100 mm juniors have – pretty...
Skypeople Fruit Juice Inc. (SPU), Lands’ End Inc. (LE) & Others: Why These Losers Are Dragging Down the Market
The markets continue to trade down in anticipation of the upcoming OPEC meeting. Another important factor affecting the markets today is the upcoming...
Why Does The Smart Money Like Acorda Therapeutics?
Acorda Therapeutics Inc (NASDAQ:ACOR) is a $1.11 billion biotechnology company that develops and commercializes novel therapies for neurological disorders...
Two Big Parkinson’s Updates From Adamas Pharmaceuticals Inc (ADMS) And Acorda Therapeutics Inc (ACOR)
We just got a couple of updates in the Parkinson’s space, and both have the potential to serve up some volatility in the market capitalisations of the...
Should You Buy Acorda Therapeutics Inc (ACOR)?
Investing in hedge funds can bring large profits, but it’s not for everybody, since hedge funds are available only for high-net-worth individuals. They...
These Oil and Biotech Stocks Are in the Crosshairs of Elite Investors
While many hedge funds are still preparing their third quarter filings with the SEC, providing the main ingredients for our delectable small-cap investment...
Kyle Bass’ War Against Pharmaceutical Companies Goes On While The Masses Overlook China’s Real Problem
Those who seek to profit from shorting strategies should keep a close eye on Kyle Bass’ war against the pharmaceutical industry. The founder of Hayman...
Acorda Therapeutics Inc (ACOR)’s Shares Jump After Dismissal Of Patent Challenge From Hedge Fund Manager Kyle Bass
The shares of Acorda Therapeutics Inc (NASDAQ:ACOR) are trading 13.16% higher today after the dismissal of a patent challenge against the company. Kyle...
Nektar Therapeutics (NKTR): Insiders Aren’t Crazy About It But Hedge Funds Love It
Is Nektar Therapeutics (NASDAQ:NKTR) a good investment? Now, according to many of your peers, hedge funds are assumed to be useless, outdated investment...
Acorda Therapeutics Inc (ACOR): Insiders Aren’t Crazy About It But Hedge Funds Love It
To many investors, hedge funds are assumed to be bloated, outdated investment tools of a forgotten age. Although there are In excess of 8,000 hedge funds...
Hedge Funds Are Selling Sarepta Therapeutics Inc (SRPT)
Is it smart to be bullish on Sarepta Therapeutics Inc (NASDAQ:SRPT)? If you were to ask many of your fellow readers, hedge funds are seen as overrated...
Alnylam Pharmaceuticals, Inc. (ALNY): Insiders Aren’t Crazy About It But Hedge Funds Love It
Who’s crazy about Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)? If you were to ask many market players, hedge funds are seen as useless, outdated...
Alnylam Pharmaceuticals, Inc. (ALNY): Here’s What The Smart Money Thinks
Is Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) the right investment to pursue these days? Hedge funds are taking a bullish view. The number of bullish...
Is Nektar Therapeutics (NKTR) Going to Burn These Hedge Funds?
Nektar Therapeutics (NASDAQ:NKTR) was in 8 hedge funds’ portfolio at the end of March. NKTR has experienced a decrease in support from the world...
Is Acorda Therapeutics Inc (ACOR) Going to Burn These Hedge Funds?
Acorda Therapeutics Inc (NASDAQ:ACOR) was in 10 hedge funds’ portfolio at the end of March. ACOR has experienced a decrease in hedge fund sentiment...
This Metric Says You Are Smart to Buy Sarepta Therapeutics Inc (SRPT)
Sarepta Therapeutics Inc (NASDAQ:SRPT) was in 19 hedge funds’ portfolio at the end of March. SRPT shareholders have witnessed an increase in enthusiasm...
Idenix Pharmaceuticals Inc (IDIX), Alnylam Pharmaceuticals, Inc. (ALNY) & 3 Small Biotechs Top Hedge Funds Are Investing In
Small biotech companies have great investment potential if you can identify them properly. A small biotech with a differentiated treatment approach and...
Vertex Pharmaceuticals Incorporated (VRTX), Gilead Sciences, Inc. (GILD): The Week, Biotech – Part Two
As I mentioned previously in Part 1, it was an incredibly busy week for the biotech sector. A PDUFA decision, as well as three FDA panel reviews/findings...
Biogen Idec Inc. (BIIB): What Goes up Must Come Down
Biogen Idec Inc. (NASDAQ:BIIB) is one of those rare companies in the healthcare sector whose stock has relentlessly outperformed the broader market continuously...
Biopharma News: Theravance Inc (THRX), VIVUS, Inc. (VVUS), Amgen, Inc. (AMGN)
Editor’s Note: Related tickers: Theravance Inc (NASDAQ:THRX), VIVUS, Inc. (NASDAQ:VVUS), Amgen, Inc. (NASDAQ:AMGN), Acorda Therapeutics Inc (NASDAQ...
Acorda Therapeutics Inc (ACOR): Insiders Are Dumping, Should You?
Acorda Therapeutics Inc (NASDAQ:ACOR) was in 10 hedge funds’ portfolio at the end of the fourth quarter of 2012. ACOR investors should pay attention...
